Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar 22;37(13):1775-1784.
doi: 10.1016/j.vaccine.2019.02.030. Epub 2019 Feb 20.

Differential durability of immune responses to measles and mumps following MMR vaccination

Richard B Kennedy  1 , Inna G Ovsyannikova  2 , Antonia Thomas  3 , Beth R Larrabee  4 , Steven Rubin  3 , Gregory A Poland  2
Affiliations

Differential durability of immune responses to measles and mumps following MMR vaccination

Richard B Kennedy et al. Vaccine. .

Abstract

The development and wide-spread use of mumps vaccine resulted in a dramatic and sustained decrease in the incidence of mumps disease; however, since 2000, an increase in the size and number of mumps outbreaks in the United States and other countries has sparked renewed interest in the durability of mumps-specific immunity elicited by mumps vaccination. The most likely explanation for mumps cases in previously immunized persons may be secondary vaccine failure, or waning immunity. In the current study, we examined changes in markers of measles and mumps immunity at two timepoints, approximately 7 and 17 years after two-dose MMR-II® vaccination, in a cohort of 98 healthy adults. Our results indicate that mumps IgG titers exhibited a large and significant decline during this time period, while mumps neutralizing Ab titers were relatively stable. There was a similar discrepancy with measles-specific immune responses. For both pathogens, neutralizing antibody titers were fairly low and, given the length of time since vaccination, may have already declined. These data suggest that specific immune outcomes may wane at different rates and highlight our currently incomplete understanding of protective immune responses to mumps and measles.

Keywords: Antibodies; Cell-mediated immunity; Humoral immunity; MMR-II vaccine; Measles; Measles vaccine; Measles virus; Mumps; Mumps vaccine; Mumps virus; T cell ELISPOT.

PubMed Disclaimer

Conflict of interest statement

Disclosures

Dr. Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being conducted by Merck Research Laboratories. Dr. Poland offers consultative advice on vaccine development to Merck & Co. Inc., Avianax, Adjuvance, Valneva, Medicago, Sanofi Pasteur, GlaxoSmithKline, and Emergent Biosolutions. Dr. Poland’s effort on this project was covered by the abovementioned NIH grants. Dr. Poland did not receive any support from the Merck Investigator Studies Program grant. Drs. Poland and Ovsyannikova hold patents related to measles and vaccinia peptide research. Dr. Kennedy holds a patent related to vaccinia peptide research. Dr. Kennedy has received funding from the Merck Investigator Studies Program to study waning immunity to mumps vaccine. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies.

Dr. Poland is the chair of a Safety Evaluation Committee for novel non-rubella investigational vaccine trials being conducted by Merck Research Laboratories. Dr. Poland offers consultative advice on vaccine development to Merck & Co. Inc., Avianax, Adjuvance, Valneva, Medicago, Sanofi Pasteur, GlaxoSmithKline, and Emergent Biosolutions. Drs. Poland and Ovsyannikova hold three patents on measles and vaccinia peptide research. Dr. Kennedy holds a patent on vaccinia peptide research. Dr. Kennedy has also received funding from Merck Research Laboratories to study waning immunity to mumps. All other authors declare no competing financial interests. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policies.

Figures

Figure 1.
Figure 1.. Measles and Mumps Serum IgG Titer and Neutralizing Ab Titer.
Virus-specific Ab titers (A and B) and neutralizing Ab titers (C and D) were measured as described in Methods. The box and whisker plots depict the median (solid line), interquartile range (boxes), and standard deviation (error bars), with the remaining data points plotted as open circles.
Figure 2.
Figure 2.. Effect of Time Since Vaccination on Neutralizing Antibody Response.
A) Mumps-specific neutralizing Ab titers were plotted as a function of time since last vaccination. B) Measles-specific neutralizing Ab titers were plotted as a function of time since last vaccination. Each subject underwent two blood draws (denoted by the red and blue circles). A linear regression line (black) was superimposed over the data.
Figure 3.
Figure 3.. Mumps Neutralizing Antibody Titers At Each Blood Draw.
A) Mumps Ab titer at the initial blood draw ~8 years-postvaccination. B) Mumps Ab titer at the second blood draw ~15 years post-vaccination. C) Difference in titer between blood draws.
Figure 4.
Figure 4.. Measles Neutralizing Antibody Titers At Each Blood Draw.
A) Measles Ab titer at the initial blood draw ~8 years post-vaccination. B) Measles Ab titer at the second blood draw ~15 years post-vaccination. C) Difference in titer between blood draws.
Figure 5.
Figure 5.. Sex Differences in Humoral Immune Response to Mumps and Measles.
A) Mumps neutralizing Ab titers in men and women. B) A) Measles neutralizing Ab titers in men and women.
Figure 6.
Figure 6.. Correlation Between Mumps and Measles-Specific Immune Response.
A) Antibody titer correlation at first blood draw. B) Antibody titer correlation at second blood draw.
Figure 7.
Figure 7.. Comparison Between Change in Ab Titer Between Pathogens.
The change in measles neutralizing Ab titer (Y-axis) is compared to the change in mumps neutralizing Ab titer (X-axis). Each data point represents a single subject.
See this image and copyright information in PMC

References

    1. Rubin S Mumps Vaccines In: Plotkin S, Orenstein W, Offit P, Edwards KM, editors. Plotkin’s VACCINES. 7th ed. Philadelphia, PA: Elsevier, 2017: pp. 663–87.
    1. Rubin S, Eckhaus M, Rennick LJ, Bamford CG, Duprex WP. Molecular biology, pathogenesis and pathology of mumps virus. J Pathol 2014. Sep 17;235(2):242–52. - PMC - PubMed
    1. Latner DR, Hickman CJ. Remembering mumps. PLoS Pathog 2015. May;11(5):e1004791. - PMC - PubMed
    1. Rafiei Tabatabaei S, Esteghamati AR, Shiva F, Fallah F, Radmanesh R, Abdinia B, et al. Detection of serum antibodies against measles, mumps and rubella after primary measles, mumps and rubella (MMR) vaccination in children. Arch Iran Med 2013. Jan;16(1):38–41. - PubMed
    1. Weibel RE, Stokes J Jr., Buynak EB, Whitman JE Jr, Hilleman MR. Live, attenuated mumps-virus vaccine. 3. Clinical and serologic aspects in a field evaluation. New Engl J of Med 1967;276:245–51. - PubMed

Publication types

MeSH terms

Substances